ResMed Limited
(ASX:RMD) has announced a definitive agreement to acquire Brightree for $800 million, a leader in business management and clinical software applications for the post-acute care industry.
The sleep apnea medical device company says the acquisition adds to ResMed’s global leadership in connected healthcare solutions.
Brightree’s cloud based software helps customers improve clinical and business performance in the post acute care industries of home/durable medical equipment, home health and hospice.
All of these are areas that have a high prevalence of sleep-disordered breathing and other chronic diseases.
ResMed reported a net profit of $459.49 million at 30 June 2015.
